Pharmacological studies targeting CXCR4/CXCL12 axis demonstrated that CXCR4 antagonist releases T cells from CXCL12-rich stroma and increases T cell infiltration to tumor sites [55–57]. Here, CXCR4 is linked to neoplasm.